This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Clinical trial NCT07162571 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07162571
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2030-12-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.